BioAtla, Inc. (BCAB)
Largest Insider Buys in Sector
BCAB Stock Price History Chart
BCAB Stock Performance
About BioAtla, Inc.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen …
Insider Activity of BioAtla, Inc.
Over the last 12 months, insiders at BioAtla, Inc. have bought $9,320 and sold $0 worth of BioAtla, Inc. stock.
On average, over the past 5 years, insiders at BioAtla, Inc. have bought $19.88M and sold $101.07M worth of stock each year.
Highest buying activity among insiders over the last 12 months: SHORT JAY M PHD (Chief Executive Officer) — $106,910. MCBRINN SYLVIA (director) — $9,320.
The last purchase of 4,000 shares for transaction amount of $9,320 was made by MCBRINN SYLVIA (director) on 2023‑12‑26.
List of Insider Buy and Sell Transactions, BioAtla, Inc.
| 2023-12-26 | director | 4,000 0.0082% | $2.33 | $9,320 | -13.66% | |||
| 2023-12-20 | Chief Executive Officer | 50,000 0.1107% | $2.14 | $106,910 | +1.47% | |||
| 2023-12-19 | See Remarks | 7,495 0.0159% | $2.04 | $15,262 | +3.04% | |||
| 2023-12-19 | director | 20,000 0.0427% | $2.05 | $41,048 | +3.04% | |||
| 2023-09-08 | director | 2,000 0.0044% | $2.54 | $5,080 | -17.05% | |||
| 2023-03-29 | Chief Executive Officer | 40,800 0.0845% | $2.47 | $100,862 | +1.79% | |||
| 2023-03-28 | See Remarks | 20,000 0.0429% | $2.40 | $47,970 | +8.51% | |||
| 2023-03-28 | director | 4,000 0.0084% | $2.35 | $9,400 | +8.51% | |||
| 2022-12-19 | director | 3,700 0.0097% | $8.33 | $30,813 | -64.47% | |||
| 2022-11-22 | director | 2,000 0.0048% | $8.27 | $16,540 | -66.02% | |||
| 2022-08-12 | Chief Executive Officer | 26,350 0.0788% | $7.84 | $206,600 | -46.78% | |||
| 2022-06-21 | Chief Executive Officer | 40,308 0.114% | $2.91 | $117,296 | +40.73% | |||
| 2022-06-07 | See Remarks | 10,000 0.0258% | $2.97 | $29,720 | +25.65% | |||
| 2021-12-02 | Sale | Chief Executive Officer | 4,811 0.0135% | $21.76 | $104,666 | -70.68% | ||
| 2021-12-02 | Sale | President | 2,984 0.0084% | $21.76 | $64,918 | -70.68% | ||
| 2021-12-02 | Sale | Chief Financial Officer | 1,434 0.004% | $21.76 | $31,198 | -70.68% | ||
| 2021-12-02 | Sale | Chief Medical Officer | 820 0.0023% | $21.76 | $17,839 | -70.68% | ||
| 2021-12-02 | Sale | See Remarks | 200 0.0006% | $21.76 | $4,351 | -70.68% | ||
| 2021-12-01 | Sale | Chief Executive Officer | 24,321 0.0763% | $23.03 | $560,226 | -69.08% | ||
| 2021-12-01 | Sale | President | 628 0.002% | $23.03 | $14,466 | -69.08% |
Insider Historical Profitability
| MCBRINN SYLVIA | director | 15125 0.0313% | $0.69 | 5 | 0 | <0.0001% |
| Cormorant Asset Management, LP | 2292060 4.741% | $0.69 | 1 | 0 | +17.46% | |
| SHORT JAY M PHD | Chief Executive Officer | 1439283 2.9771% | $0.69 | 4 | 13 | <0.0001% |
| Levy Guy | director | 217358 0.4496% | $0.69 | 1 | 2 | +17.46% |
| Vasquez Christian | See Remarks | 115659 0.2392% | $0.69 | 3 | 7 | +17.08% |
Institutional Investor Ownership
| Soleus Capital Management, L.P. | $13.98M | 8.45 | 4.07M | 0% | +$0 | 0.06 | |
| BlackRock | $9.56M | 5.78 | 2.78M | -3.62% | -$358,836.70 | <0.0001 | |
| The Vanguard Group | $7.22M | 4.36 | 2.1M | +0.85% | +$60,774.48 | <0.0001 | |
| Morgan Stanley | $6.57M | 3.97 | 1.91M | -0.15% | -$10,220.24 | <0.0001 | |
| Tang Capital Management, LLC | $5.07M | 3.06 | 1.47M | -41.6% | -$3.61M | 0.02 |